Switch View
© Globe Newswire
01.10.2025
ISIN: US34960Q3074
Fortress Biotech Inc
FBIO
LISTED
NASDAQ
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
News Preview
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) relating to the New Drug Application (“NDA”) for CUTX-101 (copper hi...
Themefolio
Profiler
Peergroup
© Newsfile
01.10.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness QSR Announces the Signing of 1st Real-Estate Location in Montreal, Quebec
News Preview
Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands is pleased to announce that Heal Wellness has signed a real-estate location in Montreal, Quebec. The location will be at 6985 Boul. Décarie, Montr...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ISIN: US50127T1097
Kura Oncology Inc
KURA
LISTED
NASDAQ
Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
News Preview
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML –...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
01.10.2025
ISIN: US12529R1077
C4 Therapeutics Inc
CCCC
LISTED
NASDAQ
C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma
News Preview
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. Under the terms of the agreement, Pfiz...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
01.10.2025
ISIN: US28658R1068
Climb Bio, Inc
CLYM
LISTED
NASDAQ
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
News Preview
WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two de...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ISIN: US7867001049
Sagimet Biosciences Inc
SGMT
LISTED
NASDAQ
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
News Preview
SAN MATEO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the Company has dosed the first participants in a Phase 1 pharmacokinetic (PK) trial of a comb...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ISIN: US09077A1060
Biomea Fusion Inc
BMEA
LISTED
NASDAQ
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
News Preview
SAN CARLOS, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that on September 24, 2025, the compensation committee of Biomea’s board of directors granted one new employee non-qualified stock options to purchase 48,000...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ISIN: US6409791000
Neumora Therapeutics Inc
NMRA
LISTED
NASDAQ
Neumora Therapeutics to Host Virtual R&D Day on October 27
News Preview
WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will host a virtual R&...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ISIN: GB00B2823H99
E-Therapeutics plc
ETX
LISTED
AIMX
e-therapeutics Relaunches as Tangram Therapeutics and Unveils LLibra OS
News Preview
Relaunch marks pivotal next step in the company’s growth, in anticipation of first CTA submission in Q4 2025....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ISIN: US09058V1035
BioCryst Pharmaceuticals Inc
BCRX
LISTED
NASDAQ
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business
News Preview
– Transaction valued at $250 million, with up to $14 million in future milestones –...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ISIN: US04335A1051
Arvinas, Inc.
ARVN
LISTED
NASDAQ
Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
News Preview
NEW HAVEN, Conn., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that two presentations, including one e-poster session and one oral platform presentation, featuring clinical data for ARV-102, an investigati...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.10.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
Medical Care Technologies (OTC Pink:MDCE) Secures Access to One of the World's Largest Public Skin Cancer Image Databases to Accelerate AI Development
News Preview
MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of advanced healthcare AI solutions, today announced that it has secured access to the International Skin Imaging Collaboration (ISIC) Archive - one of the world's largest publicly available, biopsy-verified image repositories f...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
01.10.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Total Voting Rights
News Preview
01 October 2025
LEI: 5493003YBCY4W1IMJU04
...
Themefolio
Profiler
Peergroup
© EQS Newswire
01.10.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG treibt Markteinführung neuer Produkte im ersten Halbjahr 2025 voran und baut strategische Partnerschaften aus
News Preview
PRESSEMITTEILUNG
Viromed Medical AG treibt Markteinführung neuer Produkte im ersten Halbjahr 2025 voran und baut strategische Partnerschaften aus
Rellingen, 1. Oktober 2025 – Die Viromed Medical Gruppe („Viromed“; ISIN: DE000A3MQR65), ein Medizintechnikunternehmen und Pionier der Kaltplasmatechnologie, hat ihren Halbjahresbericht 2025 veröffentli......
Themefolio
Profiler
Peergroup
© EQS Newswire
01.10.2025
ISIN: DE000A3MQR65
Viromed Medical AG
Q11
LISTED
XETRA
Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships
News Preview
PRESS RELEASE
Viromed Medical AG drives forward market launch of new products in the first half of 2025 and expands strategic partnerships
Rellingen, October 01, 2025 – Viromed Medical Group ("Viromed"; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology, has published its 2025 half-year report, which includes ......
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.10.2025
ISIN: US7389201077
Aspire Biopharma Holdings, Inc
ASBP
LISTED
NASDAQ
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication
News Preview
Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate CommercializationFuture Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL / ACCESS Newswire / October 1, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pen...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.10.2025
ISIN: US19207A1088
Coeptis Therapeutics, Inc.
COEP
LISTED
OTC
Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage
News Preview
BRISTOL, TN / ACCESS Newswire / October 1, 2025 / Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) today announced that The Vanderbilt Report has published coverage of the company following its recent SEC filings.According to disclosures filed on January 31, 2025, Coeptis' technology division was assigned a $660.3 million fair market value. In add...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
ISIN: JP3942400007
Astellas Pharma Inc
45030
LISTED
XJPX
Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
News Preview
- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs -
- Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer se...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.10.2025
ISIN: US52177H1005
Leafbuyer Technologies, Inc.
LBUY
LISTED
OTC
Leafbuyer Technologies, Inc. Announces Record Results for Fiscal Year Ending June 30th 2025
News Preview
Financial Highlights:Revenue rose 16% to $6,471,573 from $5,601,357 in the fiscal year 2025Gross Margin increased 19%Gross Profit increased 38% from $2,052,029 to $2,824,810 in the same periodOperating Expenses decreased by 4% in the same periodCash on the balance sheet increased by 416% in the same period DENVER, CO / ACCESS Newswire / October 1,...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
Telix Announces Record-Breaking Presence at EANM 2025
News Preview
MELBOURNE, Australia, Sept. 30, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its record-breaking conference presence with 28 company-related abstract presentations at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held i...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.10.2025
ISIN: US75990A2006
REMSleep Holdings, Inc.
RMSL
LISTED
OTC
Deltawave(TM) Launch Plan
News Preview
REMSleep Announces Strategic launch of the Deltawave™ CPAP Mask System BLACKSHEAR, GA / ACCESS Newswire / October 1, 2025 / RemSleep Holdings, Inc. (OTCID:RMSL) Remsleep, the developer of the FDA-Cleared Deltawave™ CPAP mask system gives shareholder update on progress and status of Deltawave™ launch.Remsleep has finalized contract...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.10.2025
ISIN: DK0061155009
Pharma Equity Group A/S
PEG
LISTED
CPH
The Board of Directors' resolution on the issuance of convertible loans
News Preview
About Pharma Equity Group A/S ...
Themefolio
Profiler
Peergroup
© Newsfile
01.10.2025
ISIN: CA74040N1069
Predictmedix AI Inc
PMED
LISTED
CSE
Predictmedix AI Launches Next-Generation Clinical-Trial AI Platform
News Preview
Adaptive "digital brain" designed to cut risk, cost and timelines in the $70-billion clinical-trials market1Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink: PMEDF) (FSE: 3QP0) ("Predictmedix" or the "Company"), an emerging leader in AI-powered health and safety technology, announced the launch of it...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
ISIN: NL0011606264
Merus N.V.
MRUS
LISTED
NASDAQ
MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus N.V. (NasdaqGM: MRUS) to Genmab A/S (NasdaqGS: GMAB). Under the terms of the proposed transaction, shareholders of Merus will receive $97.00 in cash for each share of Merus that they ow...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
ISIN: US29251M1062
Enanta Pharmaceuticals Inc
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the pricing of an upsized underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share. All of the shares are b...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
ISIN: US8835561023
Thermo Fisher Scientific Inc
TMO
LISTED
NYSE
Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes
News Preview
Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $2.5 billion aggregate principal amount (the “Offering”) of the following notes:
$500 million aggregate principal amount of its 4.200% senior notes due 2031 (the “2031 notes”) at the issue price of 99.874% of their principal amount;...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
ISIN: US8342033094
Soleno Therapeutics Inc
SLNO
LISTED
NASDAQ
Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SLNO
News Preview
NEW YORK, Sept. 30, 2025 /PRNewswire/ --
Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf o...
Themefolio
Profiler
Peergroup
© PR Newswire
01.10.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
Lantheus Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - LNTH
News Preview
LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. S...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2025
ISIN: US8036071004
Sarepta Therapeutics Inc
SRPT
LISTED
NASDAQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2025 (the “Grant Date”) that were approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 indi...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US28176E1082
Edwards Lifesciences Corp.
EW
LISTED
NYSE
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW
News Preview
NEW YORK, Sept. 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW)....
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: NL0011606264
Merus N.V.
MRUS
LISTED
NASDAQ
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of 1st Merus N.V. (NASDAQ: MRUS)
News Preview
NEW YORK, Sept. 30, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquar...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
ISIN: US88688T1007
Tilray Brands Inc
TLRY
LISTED
TSX
Tilray, leader mondial du cannabis médical, annonce l’expansion de sa gamme de cannabis Craft haut de gamme dans son centre de production en Allemagne, conforme aux normes BPF de l’UE. Tilray Medical enrichit le portefeuille de produits à base de cannabis
News Preview
NEUMÜNSTER, Allemagne, 01 oct. 2025 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique qui permet aux patients et aux professionnels de santé de prendre ensemble des décisions de santé individualisées éclairées, transformant ainsi le secteur de...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US66987V1098
Novartis AG (ADR)
NVS
LISTED
NYSE
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
News Preview
Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment
1
Well-controlled dis...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or "the Company") (NASDAQ: LNTH) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Ru...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US87911J1034
abrdn Healthcare Investors
HQH
LISTED
NYSE
ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE DISTRIBUTION PAYMENT DETAILS
News Preview
PHILADELPHIA, Sept. 30, 2025 /PRNewswire/ -- The Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below on September 30, 2025, on a per share basis t...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK) for violations of the securities laws....
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US4718711033
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
News Preview
LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Secur...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK
News Preview
LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Cytokinetics, Incorporated ("Cytokinetics" or "the Company") (NASDAQ: CYTK ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US4718711033
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - JSPR
News Preview
LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or "the Company") (NASDAQ: JSPR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Secur...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US02155H1014
Altimmune, Inc.
ALT
LISTED
NASDAQ
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: CA29668H1047
Essa Pharma, Inc.
EPIX
LISTED
NASDAQ
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
News Preview
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 30, 2025 /CNW/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, under which Xe...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: CA29668H1047
Essa Pharma, Inc.
EPIX
LISTED
NASDAQ
ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order
News Preview
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 30, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced Business Combination Agreement with XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, under w...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: US40412C1018
HCA Healthcare Inc
HCA
LISTED
NYSE
HCA Healthcare Presents 2025 Awards of Distinction
News Preview
HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today presented its annual HCA Healthcare Awards of Distinction at a ceremony in Nashville, Tennessee. The HCA Healthcare Awards of Distinction—comprising the Frist Humanitarian Award and the Excellence in Nursing Award—are the highest honors HCA Healthcare bestows...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: US0070021086
Adicet Bio Inc
ACET
LISTED
NASDAQ
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
News Preview
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on September 30, 2025.
One individual was hired by Adicet in September 2025 and granted new hire non-qualified stock options...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US29415F1049
Envista Holdings Corp
NVST
LISTED
NYSE
Envista Schedules Third Quarter 2025 Earnings Call
News Preview
BREA, Calif., Sept. 30, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its third quarter 2025 on Thursday, October 30, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one h...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: US46266C1053
IQVIA Holdings Inc
IQV
LISTED
NYSE
IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025
News Preview
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its third-quarter 2025 financial results before the market opens on Tuesday, October 28, 2025. The IQVIA management team will also host a co...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: US98978V1035
Zoetis Inc
ZTS
LISTED
NYSE
Zoetis Receives Conditional Approval for Dectomax®-CA1 Injectable for the Prevention and Treatment of New World Screwworm Myiasis in Cattle
News Preview
Zoetis Inc. today announced that Dectomax®-CA1 Injectable is the first and only parasite control product to receive conditional approval from the U.S. Food and Drug Administration for the prevention and treatment of infestations caused by the larvae of Cochliomyia hominivorax (myiasis), and prevention of reinfestation for 21 days. This conditional...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: US29251M1062
Enanta Pharmaceuticals Inc
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced it has commenced an underwritten public offering for $50.0 million of shares of its common stock. All of the shares are being offered by Enanta. In addition, Enanta i...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US00287Y1091
AbbVie Inc
ABBV
LISTED
EURONEXT
AbbVie Begins Construction on $70 Million Expansion to Further Increase Biologics Manufacturing and R&D Presence in the U.S.
News Preview
Expansion increases biologics manufacturing for immunology and oncology medicines
Milestone marks progress on
AbbVie's long-term commitment to U.S. manufacturing...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
ISIN: US7473241013
Pyxis Oncology Inc
PYXS
LISTED
NASDAQ
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 382...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: US76129W1053
Retractable Technologies, Inc.
RVP
LISTED
XASE
Retractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock Shareholders
News Preview
Retractable Technologies, Inc. (“Retractable”) (NYSE American: RVP) announced today that its Board of Directors has declared dividends to holders of its Series II Class B and Series III Class B Convertible Preferred Stock in the amounts of $39,050.00 and $18,561.25, respectively. Dividends have accrued at $1.00 per share per annum. The dividends c...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
ISIN: US47973J1025
Joint Corp
JYNT
LISTED
NASDAQ
The Joint Corp. Names Debbie L. Gonzalez Chief Marketing Officer
News Preview
- CMO with extensive experience in brand building, franchising and strategic growth – - CMO with extensive experience in brand building, franchising and strategic growth –...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
ISIN: US03168L1052
Amneal Pharmaceuticals Inc
AMRX
LISTED
NASDAQ
Amneal to Report Third Quarter 2025 Results on October 30, 2025
News Preview
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:3...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
ISIN: US90400D1081
Ultragenyx Pharmaceutical Inc
RARE
LISTED
NASDAQ
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
News Preview
NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company’s busi...
Themefolio
Profiler
Peergroup
© Globe Newswire
30.09.2025
ISIN: US75886F1075
Regeneron Pharmaceuticals Inc
REGN
LISTED
NASDAQ
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
News Preview
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: US29261A1007
Encompass Health Corp
EHC
LISTED
NYSE
Newsweek, Statista name Encompass Health "America's Most Awarded Leader in Inpatient Rehabilitation" for sixth consecutive year
News Preview
BIRMINGHAM, Ala., Sept. 30, 2025 /PRNewswire/ -- Encompass Health today announced it has been named "America's Most Awarded Leader in Inpatient Rehabilitation" by Newsweek and Statista for the sixth consecutive year. Newsweek and Statista recently released the 2025 America's Best Physical Rehabilitation Centers l...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: JP3701000006
JCR Pharmaceuticals Co., Ltd.
45520
LISTED
XJPX
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
News Preview
JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced today that it will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the European Society of Gene and Cell Therapy (ESGCT) 32...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients
News Preview
Pfizer Inc. (NYSE: PFE) today announced a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America’s role as the global leader in biopharmaceutical innovation.
In response to the four points covered in the President’s July 31st letter, Pfizer has...
Themefolio
Profiler
Peergroup
© PR Newswire
30.09.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Transaction in Own Shares
News Preview
For immediate release
30 September 2025
...
Themefolio
Profiler
Peergroup
© BusinessWire
30.09.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX INVESTIGATION ALERT: MoonLake Immunotherapeutics Trial Results Triggers Securities Fraud Investigation after Stock Plummets 90% -- Investors Urged to Contact BFA Law
News Preview
Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into MoonLake Immunotherapeutics (NASDAQ: MLTX) for potential violations of the federal securities laws.
If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics.
Wh...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
